Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chinese adults

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 194-200

  Hong, Jie ^a   Gu, Weiqiong ^a   Zhang, Yifei ^a   Yan, Qun ^a   Dai, Meng ^a   Shi, Juan ^a   Zhai, Ying ^a   Wang, Weiqing ^a   Li, Xiaoying ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adipocyte fatty acid binding protein; Coronary angiography; Coronary artery disease; Epidermal fatty acid binding protein; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; EPIDERMAL FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTES; ADULT; AGED; AGED, 80 AND OVER; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYTOPLASM; EPIDERMIS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK; RISK FACTORS;

EID: 79960241689     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.002     Document Type: Article

References (37)

1. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
2. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
3. Chmurzyńska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 2006, 47:39-48.
4. Boord J.B., Fazio S., Linton M.F. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002, 13:141-147.
5. Cabré A., Lázaro I., Girona J., et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008, 49:1746-1751.
6. Haluzík M.M., Anderlová K., Dolezalová R., et al. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 2009, 58:93-99.
7. Montoudis A., Seidman E., Boudreau F., et al. Intestinal fatty acid binding protein regulates mitochondrion beta-oxidation and cholesterol uptake. J Lipid Res 2008, 49:961-972.
8. Yeung D.C., Xu A., Tso A.W., et al. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients. Diabetes Care 2009, 32:132-134.
9. Rhee E.J., Lee W.Y., Park C.Y., et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 2009, 160:165-172.
10. Xu A., Tso A.W., Cheung B.M., et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
11. Tso A.W., Xu A., Sham P.C., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
12. Hsu B.G., Chen Y.C., Lee R.P., Lee C.C., Lee C.J., Wang J.H. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J 2010, 74:327-330.
13. Xu A., Wang Y., Xu J.Y., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
14. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H., Shin J.Y. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009, 32:147-152.
15. Krieg P., Feil S., Fürstenberger G., Bowden G.T. Tumor-specific overexpression of a novel keratinocyte lipid-binding protein. Identification and characterization of a cloned sequence activated during multistage carcinogenesis in mouse skin. J Biol Chem 1993, 268:17362-17369.
16. Yeung D.C., Wang Y., Xu A., et al. Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur Heart J 2008, 29:2156-2163.
17. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51:606.
18. Kanazawa M., Yoshiike N., Osaka T., Numba Y., Zimmet P., Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr 2002, 8:S732-S737.
19. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
20. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
21. Makowski L., Hotamisligil G.S. Fatty acid binding proteins - the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004, 134:2464S-2468S.
22. Fu Y., Luo N., Lopes-Virella M.F., Garvey W.T. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 2002, 165:259-269.
23. Maeda K., Uysal K.T., Makowski L., et al. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes 2003, 52:300-307.
24. Maeda K., Cao H., Kono K., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005, 1:107-119.
25. Cao H., Maeda K., Gorgun C.Z., et al. Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes 2006, 55:1915-1922.
26. Cabré A., Lázaro I., Girona J., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-e158.
27. Karpisek M., Stejskal D., Kotolova H., et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007, 37:637-642.
28. Miyoshi T., Doi M., Hirohata S., et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 2010 Nov, 10.. [Epub ahead of print].
29. Bagheri R., Qasim A.N., Mehta N.N., et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol 2010, 106:1118-1123.
30. Jin J., Peng D.Q., Gong H., et al. Association between adipocyte fatty acid binding proteins/adiponectin and coronary artery stenosis. Zhonghua Xin Xue Guan Bing Za Zhi 2010, 38:706-710. [article in Chinese].
31. Bu L., Salto L.M., De Leon K.J., De Leon M. Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes. Diabetes Res Clin Pract 2011, (January 31).
32. Wu T., Tian J., Cutler R.G., et al. Knockdown of FABP5 mRNA decreases cellular cholesterol levels and results in decreased apoB100 secretion and triglyceride accumulation in ARPE-19 cells. Lab Invest 2010, 90:906-914.
33. Storch J., Thumser A.E. Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 2010, 285:32679-32683.
34. Peeters W., de Kleijn D.P., Vink A., et al. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J 2010, (November 8).
35. Layne M.D., Patel A., Chen Y.H., et al. Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J 2001, 15:2733-2735.
36. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005, 280:12888-12895.
37. Furuhashi M., Tuncman G., Görgün C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.